Ovid Therapeutics (OVID) Stock Forecast & Price Target

Ovid Therapeutics is supported by a clinically validated epilepsy mechanism, with OV329 designed to preserve vigabatrin-like anti-seizure efficacy while avoiding the ocular toxicity that has constrained the only approved GABA-AT inhibitor. Its Phase 1 data across 68 healthy volunteers showed clean ophthalmology findings, no treatment-related serious adverse events, and cortical inhibition that exceeded vigabatrin at 400-600× lower dose, while cash of $169.8M as of June 30, 2026 is expected to fund operations into 2029. Beyond OV329, the first-in-class oral KCC2 activator OV4071 adds differentiated pipeline optionality, and the company’s model points to meaningful revenue opportunity in refractory focal onset seizures, TSC, and infantile spasms if upcoming readouts confirm the current signal.

Ovid Therapeutics is viewed negatively because its lead seizure assets face material safety and regulatory risks, most notably vigabatrin-class ocular toxicity that can affect up to ~30-80% of patients and is serious enough to require a boxed warning and REMS program. The company also faces common dose-related adverse events in approved adjunctive ASMs, with extension-study rates of up to ~70-95%, alongside failure of ongoing clinical trials, unexpected safety or tolerability signals, clinical and regulatory delays, and potential new competition. Fundamentally, the bear case implies the pipeline may have little residual value, with a 20% PoS across all three indications and a 12% discount rate leaving the $0.58 bear value as FY27 net cash and exercise proceeds alone, while the KCC2 pipeline (OV4071) is carried at nil.